XML 60 R62.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATIONS (Details 2) (USD $)
12 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended
Dec. 31, 2011
Buildings
Y
Dec. 31, 2011
Machinery and equipment
Y
Dec. 31, 2011
Other Equipment
Y
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Y
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Product brands
Y
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Corporate brands
Y
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Product rights
Y
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Out-licensed technology and other
Y
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Land
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Buildings
Y
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Buildings
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Machinery and equipment
Y
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Machinery and equipment
Sep. 30, 2010
Valeant Pharmaceuticals International ("Valeant")
Other Equipment
Y
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Other Equipment
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Leasehold improvements
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Construction in progress
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Ezogabine/retigabine
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Dermatology products
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Other
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Product brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Corporate brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Product rights
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized as of Acquisition Date (as previously reported)
Out-licensed technology and other
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Dermatology products
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Other
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Product brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Corporate brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Product rights
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Adjustments
Measurement Period Adjustments
Out-licensed technology and other
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Ezogabine/retigabine
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Dermatology products
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Other
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Product brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Corporate brands
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Product rights
Sep. 28, 2010
Valeant Pharmaceuticals International ("Valeant")
Amounts Recognized (as adjusted)
Out-licensed technology and other
Business Combinations                                                                                  
Fair value of accounts receivable acquired         $ 194,900,000                                                                        
Fair value of trade accounts receivable acquired         151,900,000                                                                        
Fair value of royalty and other receivable acquired         43,100,000                                                                        
Gross contractual amount of trade accounts receivable acquired         159,000,000                                                                        
Expected uncollectible of trade accounts receivable acquired         7,100,000                                                                        
Estimated fair value of inventory         78,500,000                                                                        
Useful lives, minimum (in years)   3 3                   3   3                                                    
Useful lives, maximum (in years) 40 20 10               40   20   10                                                    
Property, plant and equipment         184,757,000         23,248,000   75,008,000   64,516,000   11,003,000 3,728,000 7,254,000 184,757,000                             184,757,000              
Estimated weighted-average useful life (in years)       15   16 20 9 7                                                                
Identifiable intangible assets, excluding acquired IPR&D                                     3,844,310,000       3,114,689,000 168,602,000 360,970,000 200,049,000 (224,939,000)     (190,779,000) 98,000 (52,949,000) 18,691,000 3,619,371,000       2,923,910,000 168,700,000 308,021,000 218,740,000
Acquired IPR&D                                     $ 1,404,956,000 $ 891,461,000 $ 431,323,000 $ 82,172,000         $ (4,195,000) $ (3,100,000) $ (1,095,000)         $ 1,400,761,000 $ 891,461,000 $ 428,223,000 $ 81,077,000        
Risk-adjusted discount rate         9.00%